-

BIOCORP Announces Its Participation in Several Conferences and Congresses

ISSOIRE, France--(BUSINESS WIRE)--Regulatory News:

BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME) (Paris:ALCOR), a French company specialized in the design, development, and manufacturing of innovative medical devices, presents its agenda of investor meetings and professional conventions in the next few weeks.

  • March 23 & 24, 2022 - French-speaking Diabetes Society (SFD) Congress in Nice (France): Mallya presentation on our partners’ booth Sanofi and Roche Diabetes Care France.
  • April 5, 2022 – Investor Access in Paris (France) : Management will present the 2021 annual financial results and the 2022 outlook to investors.
  • April 27 to 30, 2022 – 15th ATTD (Advanced Technologies & Treatments for Diabetes) conference in Barcelona (Spain): BIOCORP will talk about its latest technological advances concerning Mallya.
  • May 16 & 17, 2022 – PDA Medical Devices and Connected Health Conference in Dublin (Ireland): presentation by Arnaud Guillet (Vice-President Business Development of BIOCORP): “Connected drug delivery devices - Roadmap from commercial pilots to mass adoption, use cases in different regions of the world “.
  • May 18 & 19, 2022 - Biocorp booth at Pharmapack Europe in Paris (France), the European hub of drug delivery devices industry.

ABOUT BIOCORP

Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 70 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).

For more information, please visit www.biocorpsys.com.

Contacts

BIOCORP
Jacques Gardette
Chairman of the Board
investisseurs@biocorp.fr

Éric Dessertenne
Chief Executive Officer

Sylvaine Dessard
Marketing & Communication Director
rp@biocorp.fr
+ 33 (0)6 88 69 72 85

CONTACTS ULYSSE COMMUNICATION
Bruno ARABIAN
barabian@ulysse-communication.com
+33 (0)6 87 88 46 26

Nicolas DANIELS
ndaniels@ulysse-communication.com
+33 (0)6 63 66 59 22

BIOCORP

BOURSE:ALCOR
Release Summary
BIOCORP announces its participation in several conferences and congresses
Release Versions
EnglishFrench

Contacts

BIOCORP
Jacques Gardette
Chairman of the Board
investisseurs@biocorp.fr

Éric Dessertenne
Chief Executive Officer

Sylvaine Dessard
Marketing & Communication Director
rp@biocorp.fr
+ 33 (0)6 88 69 72 85

CONTACTS ULYSSE COMMUNICATION
Bruno ARABIAN
barabian@ulysse-communication.com
+33 (0)6 87 88 46 26

Nicolas DANIELS
ndaniels@ulysse-communication.com
+33 (0)6 63 66 59 22

More News From BIOCORP

BIOCORP Obtains 510(k) FDA Clearance for SoloSmart®, Sanofi’s Smart Cap for Disposable Insulin Pens

ISSOIRE, France--(BUSINESS WIRE)--Press Release BIOCORP (Paris:ALCOR), a Novo Nordisk company based in France and specialized in the design, development, and manufacturing of innovative medical devices, announced today that they have received 510(K) clearance from the U.S. Food & Drug Administration (FDA) to market SoloSmart®, Sanofi’s smart medical device that connects SoloStar® insulin pens. Eric Dessertenne, CEO of BIOCORP, said: "This approval is a major achievement for SoloSmart and ou...

BIOCORP Reports Half-year Results as of June 30, 2023

ISSOIRE, France--(BUSINESS WIRE)--Regulatory News: BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME) (Paris:ALCOR), a French company specialized in the design, development, and manufacturing of innovative medical devices, presents its half-year financial results as of June 30, 20231. Éric Dessertenne, CEO of BIOCORP, commented: “The first half of 2023 has been very dynamic for Biocorp with the main event being the conclusion of discussions with NOVO NORDISK, our commercial partner of the Mallya...

Completion of Novo Nordisk's Acquisition of a Controlling Stake in BIOCORP

ISSOIRE, France--(BUSINESS WIRE)--Regulatory News: Following the announcement of the planned acquisition of BIOCORP Production SA (FR0012788065 - ALCOR) (“BIOCORP”) by NOVO NORDISK (DK0060534915 - Novo-B), a leading global healthcare company headquartered in Denmark and developing treatments against diabetes and other chronic diseases (“NOVO NORDISK”), released on June 5, 2023, BIOCORP announces that, following receipt of customary regulatory approvals, NOVO NORDISK has today completed the off-...
Back to Newsroom